Eli Lilly
stock was falling Thursday as sales in the pharmaceutical company’s much-hyped obesity drug came up short. Fourth-quarter earnings, however, did crush estimates.
Shares in
Eli Lilly
(ticker: LLY) fell 2.9% in premarket trading. Futures tracking the
S&P 500
were rising 0.5%, by comparison.
Source link
